Dymon Asia Capital Singapore PTE. LTD. Has $1.15 Million Position in Danaher Corporation $DHR

Dymon Asia Capital Singapore PTE. LTD. cut its position in Danaher Corporation (NYSE:DHR) by 37.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,000 shares of the conglomerate’s stock after selling 3,000 shares during the quarter. Dymon Asia Capital Singapore PTE. LTD.’s holdings in Danaher were worth $1,145,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank Pictet & Cie Europe AG lifted its stake in Danaher by 25.4% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 366,481 shares of the conglomerate’s stock valued at $83,895,000 after purchasing an additional 74,301 shares during the last quarter. Maxi Investments CY Ltd bought a new position in Danaher in the 3rd quarter valued at approximately $3,251,000. Defender Capital LLC. bought a new position in Danaher in the 4th quarter valued at approximately $35,715,000. CIBC Bancorp USA Inc. bought a new position in Danaher in the 3rd quarter valued at approximately $17,480,000. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in Danaher by 303.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate’s stock valued at $56,777,000 after purchasing an additional 186,584 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Down 0.5%

Shares of NYSE DHR opened at $179.95 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.52 and a current ratio of 1.87. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The firm has a 50 day moving average price of $180.93 and a two-hundred day moving average price of $204.78. The stock has a market cap of $127.37 billion, a P/E ratio of 34.81, a price-to-earnings-growth ratio of 2.40 and a beta of 0.81.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, April 20th. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The firm had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same period in the prior year, the company posted $1.88 EPS. The company’s revenue was up 3.7% on a year-over-year basis. As a group, equities analysts forecast that Danaher Corporation will post 8.45 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.9%. The ex-dividend date is Friday, June 26th. Danaher’s dividend payout ratio is 30.95%.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
• Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
• Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

Wall Street Analyst Weigh In

DHR has been the subject of several research reports. Wolfe Research downgraded shares of Danaher from an “outperform” rating to a “peer perform” rating in a research note on Monday, June 1st. DZ Bank initiated coverage on shares of Danaher in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 price objective for the company. TD Cowen dropped their price objective on shares of Danaher from $245.00 to $240.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Jefferies Financial Group reissued a “buy” rating and issued a $245.00 price objective on shares of Danaher in a research note on Tuesday, April 21st. Finally, Evercore increased their price objective on shares of Danaher from $225.00 to $232.00 and gave the company an “outperform” rating in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Danaher has an average rating of “Moderate Buy” and an average target price of $233.61.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.